JP2020526553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526553A5 JP2020526553A5 JP2020501279A JP2020501279A JP2020526553A5 JP 2020526553 A5 JP2020526553 A5 JP 2020526553A5 JP 2020501279 A JP2020501279 A JP 2020501279A JP 2020501279 A JP2020501279 A JP 2020501279A JP 2020526553 A5 JP2020526553 A5 JP 2020526553A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- aln
- composition according
- body weight
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023134504A JP7767365B2 (ja) | 2017-07-13 | 2023-08-22 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
| JP2025182212A JP2026035588A (ja) | 2017-07-13 | 2025-10-29 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532176P | 2017-07-13 | 2017-07-13 | |
| US62/532,176 | 2017-07-13 | ||
| US201762581565P | 2017-11-03 | 2017-11-03 | |
| US62/581,565 | 2017-11-03 | ||
| US201862646285P | 2018-03-21 | 2018-03-21 | |
| US62/646,285 | 2018-03-21 | ||
| US201862682020P | 2018-06-07 | 2018-06-07 | |
| US62/682,020 | 2018-06-07 | ||
| PCT/US2018/041891 WO2019014491A1 (en) | 2017-07-13 | 2018-07-12 | METHODS OF INHIBITING GENE EXPRESSION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023134504A Division JP7767365B2 (ja) | 2017-07-13 | 2023-08-22 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526553A JP2020526553A (ja) | 2020-08-31 |
| JP2020526553A5 true JP2020526553A5 (https=) | 2021-08-12 |
| JP7337044B2 JP7337044B2 (ja) | 2023-09-01 |
Family
ID=65002248
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501279A Active JP7337044B2 (ja) | 2017-07-13 | 2018-07-12 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
| JP2023134504A Active JP7767365B2 (ja) | 2017-07-13 | 2023-08-22 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
| JP2025182212A Pending JP2026035588A (ja) | 2017-07-13 | 2025-10-29 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023134504A Active JP7767365B2 (ja) | 2017-07-13 | 2023-08-22 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
| JP2025182212A Pending JP2026035588A (ja) | 2017-07-13 | 2025-10-29 | Ｈａｏ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子発現の阻害方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11261447B2 (https=) |
| EP (1) | EP3651775A4 (https=) |
| JP (3) | JP7337044B2 (https=) |
| AU (2) | AU2018301829B2 (https=) |
| CA (1) | CA3069451A1 (https=) |
| WO (1) | WO2019014491A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI864340B (zh) | 2014-10-10 | 2024-12-01 | 美商艾爾妮蘭製藥公司 | 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法 |
| WO2016205323A1 (en) | 2015-06-18 | 2016-12-22 | Alnylam Pharmaceuticals, Inc. | Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
| CA3069451A1 (en) | 2017-07-13 | 2019-01-17 | Alnylam Pharmaceuticals, Inc. | Methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
| AU2020376792B2 (en) | 2019-11-01 | 2025-10-02 | Lilac Therapeutics, Inc. | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors |
| EP4121534A1 (en) * | 2020-03-18 | 2023-01-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
| EP4232581A1 (en) * | 2020-10-21 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
| WO2022119873A1 (en) * | 2020-12-01 | 2022-06-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
| EP4043018A1 (en) | 2021-02-10 | 2022-08-17 | Charité - Universitätsmedizin Berlin | Composition and method for reducing oxalate levels in patients receiving maintenance dialysis |
| WO2023003805A1 (en) * | 2021-07-19 | 2023-01-26 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder |
| CN118460656B (zh) * | 2024-07-10 | 2024-12-06 | 凯莱英医药集团（天津）股份有限公司 | 一种Lumasiran的制备方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002081628A2 (en) | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| US20040259247A1 (en) | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20050176025A1 (en) | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
| US20030170891A1 (en) | 2001-06-06 | 2003-09-11 | Mcswiggen James A. | RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US7956176B2 (en) | 2002-09-05 | 2011-06-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| EP2305812A3 (en) | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| WO2004080406A2 (en) | 2003-03-07 | 2004-09-23 | Alnylam Pharmaceuticals | Therapeutic compositions |
| AU2004227414A1 (en) | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals | iRNA conjugates |
| AU2004263830B2 (en) | 2003-06-13 | 2008-12-18 | Alnylam Pharmaceuticals, Inc. | Double-stranded ribonucleic acid with increased effectiveness in an organism |
| AU2005222965B8 (en) | 2004-03-15 | 2010-07-01 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| US7642348B2 (en) | 2004-10-04 | 2010-01-05 | Rosetta Genomics Ltd | Prostate cancer-related nucleic acids |
| EP1866414B9 (en) | 2005-03-31 | 2012-10-03 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
| US7718629B2 (en) | 2006-03-31 | 2010-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 gene |
| US8598333B2 (en) | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
| WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
| WO2010147992A1 (en) | 2009-06-15 | 2010-12-23 | Alnylam Pharmaceuticals, Inc. | Methods for increasing efficacy of lipid formulated sirna |
| US20110045593A1 (en) | 2009-08-19 | 2011-02-24 | TransAlgae (Israel) Ltd. | Transgenically mitigating the establishment and spread of transgenic algae in natural ecosystems by suppressing the activity of carbonic anhydrase |
| DK2539451T3 (da) | 2010-02-24 | 2016-04-04 | Arrowhead Res Corp | Sammensætninger til målrettet tilførsel af siRNA |
| US8945847B2 (en) | 2010-05-24 | 2015-02-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for ascertaining biosafety of an agent |
| EP2780454A2 (en) | 2011-11-18 | 2014-09-24 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
| HUE048622T2 (hu) | 2011-11-18 | 2020-08-28 | Alnylam Pharmaceuticals Inc | RNSi szerek, készítmények és alkalmazási eljárások transztiretin (TTR) asszociált betegségek kezelésére |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| AU2013299717B2 (en) | 2012-08-06 | 2018-06-28 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated RNA agents and process for their preparation |
| CA3216595A1 (en) | 2013-03-14 | 2014-10-02 | Kevin Fitzgerald | Complement component c5 irna compositions and methods of use thereof |
| WO2015100436A1 (en) | 2013-12-27 | 2015-07-02 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna |
| TWI864340B (zh) * | 2014-10-10 | 2024-12-01 | 美商艾爾妮蘭製藥公司 | 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法 |
| WO2016205323A1 (en) | 2015-06-18 | 2016-12-22 | Alnylam Pharmaceuticals, Inc. | Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
| TW201718857A (zh) * | 2015-09-14 | 2017-06-01 | 艾爾妮蘭製藥公司 | 用於抑制alas1基因表現之組合物及方法 |
| CA3069451A1 (en) | 2017-07-13 | 2019-01-17 | Alnylam Pharmaceuticals, Inc. | Methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
-
2018
- 2018-07-12 CA CA3069451A patent/CA3069451A1/en active Pending
- 2018-07-12 US US16/630,800 patent/US11261447B2/en active Active
- 2018-07-12 JP JP2020501279A patent/JP7337044B2/ja active Active
- 2018-07-12 WO PCT/US2018/041891 patent/WO2019014491A1/en not_active Ceased
- 2018-07-12 AU AU2018301829A patent/AU2018301829B2/en active Active
- 2018-07-12 EP EP18831099.9A patent/EP3651775A4/en active Pending
-
2022
- 2022-01-20 US US17/579,655 patent/US20220403394A1/en active Pending
-
2023
- 2023-08-22 JP JP2023134504A patent/JP7767365B2/ja active Active
-
2024
- 2024-10-21 AU AU2024227498A patent/AU2024227498A1/en active Pending
-
2025
- 2025-10-29 JP JP2025182212A patent/JP2026035588A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020526553A5 (https=) | ||
| Wedemeyer et al. | Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| JP2014530226A5 (https=) | ||
| JP2019196370A5 (https=) | ||
| JP2011519364A5 (https=) | ||
| EP4707394A3 (en) | Rnai agents for hepatitis b virus infection | |
| NO20090887L (no) | Fremgangsmate for behandling og forebygging av mukositt | |
| JP2017503820A5 (https=) | ||
| RU2015100529A (ru) | Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомный иринотекан | |
| JP2016530279A5 (https=) | ||
| IL320452A (en) | Combination therapy for prostate cancer | |
| JP2018514510A5 (https=) | ||
| JP2018538306A5 (https=) | ||
| MX2022006742A (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter. | |
| EP4342985A3 (en) | Pharmaceutical composition for preventing or treating cancer comprising anticancer virus and hydroxyurea as effective components | |
| TNSN06308A1 (en) | Macrocyclic compounds as inhibitors of viral replication | |
| FI3930686T3 (fi) | Uusia rautakoostumuksia ja menetelmiä niiden valmistamiseksi ja käyttämiseksi | |
| JP2022501332A5 (https=) | ||
| EA201101036A1 (ru) | Применение хлорида аммония в терапии | |
| JP2021004249A5 (https=) | ||
| CA3156680A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETT SYNDROME | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| PH12021552573A1 (en) | Long-term stable live fecal microbiota composition | |
| JP2011500650A5 (https=) |